Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 55 , ISSUE 1 ( January-March, 2021 ) > List of Articles

INVITED ARTICLE

Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences

Aradhana Aneja, Sadhna B Lal

Keywords : Children, Nonalcoholic fatty liver disease,Advances in pNAFLD

Citation Information : Aneja A, Lal SB. Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences. J Postgrad Med Edu Res 2021; 55 (1):39-52.

DOI: 10.5005/jp-journals-10028-1429

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as the commonest liver disease in children. The entire spectrum of NAFLD from simple steatosis to inflammation and fibrosis is seen in children. Pediatric NAFLD (pNAFLD) is most common in preadolescent and adolescent children and has the potential to cause severe liver-related as well as cardiovascular morbidity in young adulthood. The natural history of pNAFLD needs further elucidation. However, early diagnosis is imperative to prevent serious later outcomes. Lifestyle modification through diet and exercise remains the cornerstone in the management of pNAFLD. There is a great potential for the development of noninvasive biomarkers for diagnosis and novel pharmacotherapy to become available for the treatment of pNAFLD shortly.


PDF Share
  1. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148(3):547–555. DOI: 10.1053/j.gastro.2014.11.039.
  2. Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading Indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2018;16(8):1356–1358. DOI: 10.1016/j.cgh.2017.11.045.
  3. Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 2015;10(10):e0140908. DOI: 10.1371/journal.pone.0140908.
  4. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118(4):1388–1393. DOI: 10.1542/peds.2006-1212.
  5. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64(2):319–334. DOI: 10.1097/MPG.0000000000001482.
  6. World Health Organization (WHO). Comprehensive Implementation Plan on Maternal, Infant and Young Child Nutrition. Geneva: WHO; 2014 https://www.who.int/nutrition/publications/CIP_document/en.
  7. Di Cesare M, Sorić M, Bovet P, et al. The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med 2019;17(1):212. DOI: 10.1186/s12916-019-1449-8.
  8. Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9(3):152–161. DOI: 10.1038/nrgastro.2011.273.
  9. Das MK, Bhatia V, Sibal A, et al. Prevalence of nonalcoholic fatty liver disease in normal-weight and overweight preadolescent children in Haryana, India. Indian Pediatr 2017;54(12):1012–1016. DOI: 10.1007/s13312-017-1202-3.
  10. Pawar S, Vinay Z, Choksey A, et al. Most overweight and obese Indian children have nonalcoholic fatty liver disease. Ann Hepatol 2016;15:853–861.
  11. Gupta N, Jindal G, Nadda A, et al. Prevalence and risk factors for nonalcoholic fatty liver disease in obese children in rural Punjab, India. J Family Community Med 2020;27(2):103–108. DOI: 10.4103/jfcm.JFCM_287_19.
  12. Seth A, Orkin S, Yodoshi T, et al. Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease. Paediatric Obesity 2019(2):1–8. DOI: 10.1111/ijpo.12581.
  13. Bloch AM, Schrag C, Faessler E, et al. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med 2014;189(10):66–76. DOI: 10.1164/rccm.201304-0635IM.
  14. Sundaram SS, Sokol RJ, Capocelli KE, et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr 2014;164(4):699.e1–706.e1. DOI: 10.1016/j.jpeds.2013.10.072.
  15. Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67(1):123–133. DOI: 10.1002/hep.29466.
  16. Selvakumar PKC, Kabbany MN, Nobili V, et al. Nonalcoholic fatty liver disease in children: hepatic and extrahepatic complications. Pediatr Clin North Am 2017;64(3):659–675. DOI: 10.1016/j.pcl.2017. 01.008.
  17. Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016;65(8):1017–1025. DOI: 10.1016/j.metabol.2016.01.012.
  18. Goyal NP, Schwimmer JB. The progression and natural history of paediatric non alcoholic fatty liver disease. Clin Liver Dis 2016;20(2):325–338. DOI: 10.1016/j.cld.2015.10.003.
  19. Brumbaugh DE, Tearse P, Cree-Green M, et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 2013;162(5):930–936. DOI: 10.1016/j.jpeds.2012.11.017.
  20. Modi N, Murgasova D, Ruager-Martin R, et al. The influence of maternal body mass index on infant adiposity and hepatic lipid content. Pediatr Res 2011;70(3):287–291. DOI: 10.1203/PDR.0b013e318225f9b1.
  21. Patel KR, White FV, Deutsch GH. Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr 2015;60(2):152–158. DOI: 10.1097/MPG.0000000000000520.
  22. A-Kader HH, Henderson J, Vanhoesen K, et al. Nonalcoholic fatty liver disease in children: a single center experience. Clin Gastroenterol Hepatol 2008;6(7):799–802. DOI: 10.1016/j.cgh.2008.03.001.
  23. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58(11):1538–1544. DOI: 10.1136/gut.2008.171280.
  24. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305(16):1659–1668. DOI: 10.1001/jama.2011.520.
  25. Xanthakos SA, Lavine JE, Yates KP, et al. Progression of fatty liver disease in children receiving standard of care lifestyle advice. Gastroenterology 2020(5). DOI: 10.1053/j.gastro.2020.07.034.Online ahead of print.
  26. Nobili V, Alisi A, Grimaldi C, et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatric Obesity 2014;9(5):e99–e102. DOI: 10.1111/j.2047-6310.2013.00209.x.
  27. Cioffi C, Welsh J, Cleeton R, et. al. Natural history of NAFLD diagnosed in childhood: a single-center study. Children 2017;4(5):34. DOI: 10.3390/children4050034.
  28. Gökçe S, Atbinici Z, Aycan Z, et al. The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. Pediatr Cardiol 2013;34(2):308–315. DOI: 10.1007/s00246-012-0447-9.
  29. Pacifico L, Nobili V, Anania C, et al. Paediatric non alcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011;17(26):3082–3091.
  30. Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci 2015;16(12):5161–5179. DOI: 10.3390/ijms16035161.
  31. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136(5):1585–1592. DOI: 10.1053/j.gastro.2009.01.050.
  32. Caussy C, Soni M, Cui J, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127(7):2697–2704. DOI: 10.1172/JCI93465.
  33. Rosaria G, Umano R, Mariangela Martino M, et al. The association between paediatric NAFLD and common genetic variants. Children 2017;4(6):49. DOI: 10.3390/children4060049.
  34. Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16(9):517–530. DOI: 10.1038/s41575-019-0169-z.
  35. Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012;55(3):781–789. DOI: 10.1002/hep.24806.
  36. Liu CH, Ampuero J, Gil-Gómez A, et al. miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2018;69(6):1335–1348. DOI: 10.1016/j.jhep.2018.08.008.
  37. Schwimmer JB, Johnson JS, Angeles JE, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 2019;157(4):1109–1122. DOI: 10.1053/j.gastro.2019.06.028.
  38. Soderborg TK, Clark SE, Mulligan CE, et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun 2018;9(1):4462. DOI: 10.1038/s41467-018-06929-0.
  39. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357. DOI: 10.1002/hep.29367.
  40. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN hepatology committee. JPGN 2012;54(5):700–713. DOI: 10.1097/MPG.0b013e318252a13f.
  41. Nobili V, Alisi A, Newton KP, et al. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology 2016;150(8):1798–1810. DOI: 10.1053/j.gastro.2016.03.009.
  42. Alkhouri N, De Vito R, Alisi A, et al. Development and validation of a new histologic score for paediatric non alcoholic fatty liver disease. J Hepatol 2012;57(6):1312–1318. DOI: 10.1016/j.jhep.2012.07.027.
  43. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologic scoring system for non alcoholic fatty liver disease. Hepatology 2005;41(6):1313–1321. DOI: 10.1002/hep.20701.
  44. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156(5):1264–1281. DOI: 10.1053/j.gastro.2018.12.036.
  45. Alkhouri N, Carter–Kent C, Lopez R, et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol 2011;9(2):150–155. DOI: 10.1016/j.cgh.2010.09.015.
  46. Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019;5(1):11–21. DOI: 10.5114/ceh.2019.83152.
  47. Di Sessa A, Cirillo G, Guarino S, et al. Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. Pediat Health, Med Therapeut 2019;10:89–97. DOI: 10.2147/PHMT.S188989.
  48. Walenbergh SMA, Houben T, Hendrikx T, et al. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation. Am J Gastroenterol 2015;110(3):462–470. DOI: 10.1038/ajg.2015.29.
  49. Desai NK, Harney S, Raza R, et al. Comparison of controlled attenuation parameter and liver biopsy to assess hepatic steatosis in pediatric patients. J Pediatr 2016;173:160–164. DOI: 10.1016/j.jpeds.2016.03.021.
  50. Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2015;61(6):1887–1895. DOI: 10.1002/hep.27666.
  51. Middleton MS, Van Natta ML, Heba ER, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2018;67(3):858–872. DOI: 10.1002/hep.29596.
  52. Di Martino M, Pacifico L, Bezzi M, et al. Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents. World J Gastroenterol 2016;22(39):8812–8819. DOI: 10.3748/wjg.v22.i39.8812.
  53. Cho Y, Tokuhara D, Morikawa H, et al. Transient elastography-based liver profiles in a hospital-based pediatric population in Japan. PLoS ONE 2015;10(9):e0137239. DOI: 10.1371/journal.pone.0137239.
  54. Mansoor S, Collyer E, Alkhouri N. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2015;17(6):23. DOI: 10.1007/s11894-015-0447-z.
  55. Hanquinet S, Courvoisier D, Kanavaki A, et al. Acoustic radiation force impulse imaging-normal values of liver stiffness in healthy children. Pediatr Radiol 2013;43(5):539–544. DOI: 10.1007/s00247-012- 2553-5.
  56. Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA 2019;321(3):256–265.
  57. Anania C, Perla FM, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018;24(19):2083–2094. DOI: 10.3748/wjg.v24.i19.2083.
  58. Lee S, Bacha F, Hannon T, et al. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes 2012;61(11):2787–2795. DOI: 10.2337/db12-0214.
  59. González-Ruiz K, Ramírez-Vélez R, Correa-Bautista JE, et al. The effects of exercise on abdominal fat and liver enzymes in pediatric obesity: a systematic review and meta-analysis. Child Obes 2017;13: 272–282.
  60. Mameli C, Krakauer JC, Krakauer NY, et al. Effects of a multidisciplinary weight loss intervention in overweight and obese children and adolescents: 11 years of experience. PLoS ONE 2017;12(7):e0181095. DOI: 10.1371/journal.pone.0181095.
  61. van der Heijden LB, Feskens EJM, Janse A. Maintenance interventions for overweight or obesity in children: a systematic review and meta-analysis. J Obes Rev 2018;19(6):798–809. DOI: 10.1111/obr. 12664.
  62. Schwimmer JB, Lavine JE, Wilson LA, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology 2016;151(6):1141–1154. DOI: 10.1053/j.gastro.2016.08.027.
  63. Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013;23(11):1066–1070. DOI: 10.1016/j.numecd.2012.10.010.
  64. Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2015;25(8):734–741. DOI: 10.1016/j.numecd.2015.04.003.
  65. Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr 2015;166(6):1358–63.e1-3. DOI: 10.1016/j.jpeds.2015.01.056.
  66. Vajro P, Mandato C, Licenziati MR, et al. Effects of lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;52(6):740–743. DOI: 10.1097/MPG.0b013e31821f9b85.
  67. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014;39(11): 1276–1285.
  68. Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr 2017;64(3):413–417. DOI: 10.1097/MPG.0000000000001422.
  69. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (London, England) 2015;385(9972):956–965. DOI: 10.1016/S0140-6736(14)61933-4.
  70. Ratziu V, Sanyal AJ, Loomba R, et al. Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803. DOI: 10.1016/j.cct.2019.06.017.
  71. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150(5):1147–1159.e5. DOI: 10.1053/j.gastro.2016.01.038.
  72. ClinicalTrials.gov. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) (RESOLVE-IT). https://clinicaltrials.gov/ct2/show/NCT02704403. Identifier: NCT02704403.
  73. Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12(12):2085–2091. DOI: 10.1016/j.cgh.2014.04.038.
  74. US National Library of Medicine Clinical Trials.gov http://www.clinicaltrials.gov/ct2/show/NCT03467217(2019).
  75. Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 2016;14(2):113–123. DOI: 10.1056/NEJMoa1506699.
  76. Manco M, Mosca A, de Peppo F, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr 2017;180:31–37. DOI: 10.1016/j.jpeds.2016. 08.101.
  77. Baroncini LAV, Sylvestre LC, Baroncini CV, et al. Assessment of carotid intima-media thickness as an early marker of vascular damage in hypertensive children. Arq Bras Cardiol 2017;108(5):452–457. DOI: 10.5935/abc.20170043.
  78. Rasool A, Dar W, Latief M, et al. Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis. Brain Circulation 2017;3(1):35–40.
  79. Zhou YY, Zhou XD, Wu SJ, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Communicat 2018;2(4):376–392. DOI: 10.1002/hep4.1155.
  80. Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016;170(10):e161971. DOI: 10.1001/jamapediatrics. 2016.1971.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.